Multiple Myeloma Update — Part 1: Our interview with Dr Rajkumar
highlights the following topics as well as cases from his
practice:
Updated risk-stratification model for smoldering multiple
myeloma (MM) incorporating the revised International Myeloma
Working Group diagnostic criteria; therapeutic approach for
standard- versus high-risk smoldering MM (00:00)
Subcutaneous versus intravenous daratumumab administration for
MM (05:28)
Efficacy and tolerability of the recently FDA-approved regimen
of daratumumab in combination with lenalidomide and dexamethasone
for patients with previously untreated MM not eligible for
autologous stem cell transplantation (ASCT) (06:52)
Activity, tolerability and ongoing trials of carfilzomib- and
bortezomib-based triplet regimens for newly diagnosed MM
(08:55)
Results of the Phase III CASSIOPEIA study:
Bortezomib/thalidomide/dexamethasone with or without daratumumab
for patients with newly diagnosed MM eligible for ASCT (12:39)
Case: A man in his early 80s with MM initially
treated with lenalidomide/bortezomib/dexamethasone and maintenance
lenalidomide experiences relapse 2 years later (15:02)
Benefits and risks of the Bcl-2 inhibitor venetoclax in
combination with bortezomib/dexamethasone for relapsed/refractory
(R/R) MM with and without the t(11;14) translocation on the Phase
III BELLINI trial (16:43)
Proposed mechanism of venetoclax-associated mortality in MM
(19:35)
Understanding the clinical role and limitations of surrogate
endpoints for overall survival (24:29)
Perspective on the possible design flaws in the BELLINI trial
(28:08)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.